首页4DX • ASX
4DMedical Ltd
$0.60
1月28日, GMT+11 07:36:37 · AUD · ASX · 免责声明
股票在AU上市的证券
昨日收盘价
$0.56
当日价格范围
$0.59 - $0.63
年度波幅
$0.41 - $0.83
市值
2.51亿 AUD
平均交易量
90.48万
市盈率
-
股息率
-
主要交易所
ASX
市场资讯
财务信息
损益表
收入
净收入
(AUD)2024年6月年同比变化
收入
148.09万1,172.70%
经营支出
1256.17万11.42%
净收入
-1018.61万-33.78%
净利润率
-687.8489.49%
每股收益
息税折旧摊销前利润
-1109.48万-5.51%
有效税率
-0.01%
总资产
负债总额
(AUD)2024年6月年同比变化
现金及短期投资
3060.61万-56.01%
总资产
1.20亿29.16%
负债总额
4908.88万128.71%
权益总额
7092.66万
发行在外的股份
4.11亿
市净率
3.32
资产回报率
-23.28%
资本回报率
-36.73%
现金净变动
(AUD)2024年6月年同比变化
净收入
-1018.61万-33.78%
来自运营的现金
-806.31万8.54%
投资现金
-33.95万-21.29%
融资现金
-23.40万-101.11%
现金净变动
-863.66万-172.48%
自由现金流
-543.18万13.25%
简介
4DMedical is a medical technology company, based in Australia and the United States. 4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report. 4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
成立时间
2013
员工数量
145
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单